Retatrutide Powder

Shaanxi Yuantai Biological Technology Co., Ltd. is one of the most reliable manufacturers and suppliers of retatrutide powder in China. With abundant experience, we warmly welcome you to wholesale bulk retatrutide powder for sale here from our factory. Quality products and reasonable price are available.

Retatrutide is a triple agonist peptide targeting glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic peptide receptor (GIPR), and glucagon receptor (GCGR). With its multiple benefits of lowering blood sugar, reducing weight, and improving metabolism, it holds promise as a core ingredient in the treatment of metabolic diseases.

YTBIO supplies Retatrutide with 98% purity. We offer flexible packaging from milligram to gram levels, support customized services, and provide complete Certificate of Account (COA) and MSDS documentation with each shipment. Please contact us for sample testing.

To understand the mechanism of action of Retatrutide, it is first necessary to know what a receptor agonist is. Let's start with a quick definition of receptors; they are protein molecules that are present on the surface of our pores. These receptors receive signals from outside the cell; the signal can come from a neurotransmitter, a hormone, or a drug. These substances can bind to the receptors and pass the message to our cells. When our cells receive the message, they activate and take action. For example, appetite-related hormones such as ghrelin or leptin hormones stimulate our appetite or let our cells know that we are full after a meal, respectively. Without receptors, our cells cannot receive this information.

The mechanism of action of retatrutide is based on the simultaneous activation of three metabolic regulatory receptors: GLP-1R, GIPR, and GCGR. GLP-1R activation promotes insulin secretion and delays gastric emptying in a glucose-dependent manner, achieving precise blood glucose control; GIPR activation enhances peripheral tissue insulin sensitivity and promotes glucose uptake by adipose tissue; and GCGR activation directly participates in energy expenditure by regulating hepatic glucose output and promoting lipid breakdown. The synergistic effect of these three targets enables retatrutide to exhibit a comprehensive metabolic improvement effect in clinical practice that surpasses that of single- or dual-target drugs.

Hormonal responses to nutrient intake are key regulators of metabolism. The most well-known is insulin secretion in response to increased postprandial glucose or amino acid levels, promoting nutrient storage and maintaining normal blood sugar. In addition, gut hormone responses to food intake further amplify insulin secretion (e.g., the "incretin effect" mediated by glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) to regulate aspects of satiety, food intake, and meal metabolism. Glucagon (GCG) has a powerful catabolic effect that stimulates lipolysis, reduces food intake, slows gastric emptying, and increases energy expenditure. Retaglutide can activate GLP-1, GIP, and GCG receptors, and triple G agonists are theoretically superior to single or dual agonists in reducing weight, reducing hepatic steatosis, and normalizing blood sugar levels.

In a clinical trial of 388 participants with a BMI >30 or a BMI 27 to 30 who had at least one weight-related condition, the highest dose of retaglutide resulted in average weight loss of 18% at 24 weeks and 24% at 48 weeks, compared with an average weight loss of about 2% at both time points for the placebo group. At the highest dose, 26% of participants lost more than 30% of their body weight at 48 weeks, with greater weight loss in participants with a BMI greater than 35. Multiple measures of cardiometabolic risk improved, including blood pressure and levels of glycated hemoglobin, fasting glucose, insulin, total and low-density lipoprotein cholesterol, and triglycerides.

Retaglutide clinical trial results

The benefits of the triple agonist also extended to the treatment of nonalcoholic fatty liver disease. In a subgroup of 98 participants with nonalcoholic fatty liver disease in the trial, 90% of participants in the highest dose of retaglutide group had normalized liver fat content.
Because obesity is a chronic disease (similar to high blood pressure), it is necessary to manage it with long-term treatment.

YTBIO supplies Retatrutide Powder has advantages.Professional Retatrutide suppliers.The company was established in 2014 and has many years of experience in R&D and production. We are committed to the R&D, production and sales of raw materials for the health industry in the 21st century. The certificates obtained so far include ISO9001, ISO22000, HALAL, KOSHER, HACCP, FDA, etc. We always maintain the highest demands on product quality.

Hot Tags: retatrutide powder, China retatrutide powder manufacturers, suppliers, factory